3 Stocks Underperforming Today In The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 83 points (0.5%) at 16,304 as of Monday, Dec. 23, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,307 issues advancing vs. 673 declining with 118 unchanged.

The Health Care sector currently sits up 1.1% versus the S&P 500, which is up 0.6%. Top gainers within the sector include United Therapeutics Corporation ( UTHR), up 24.1%, Illumina ( ILMN), up 2.3%, Actavis ( ACT), up 2.2%, Vertex Pharmaceuticals ( VRTX), up 2.0% and Humana ( HUM), up 1.7%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector lower today. As of noon trading, Novo Nordisk A/S is down $0.94 (-0.5%) to $179.08 on light volume. Thus far, 93,168 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 276,100 shares. The stock has ranged in price between $178.79-$179.78 after having opened the day at $179.56 as compared to the previous trading day's close of $180.02.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $95.2 billion and is part of the drugs industry. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 10.1% year to date as of the close of trading on Friday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, HCA Holdings ( HCA) is down $0.78 (-1.7%) to $46.11 on light volume. Thus far, 764,225 shares of HCA Holdings exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $45.92-$47.07 after having opened the day at $46.91 as compared to the previous trading day's close of $46.89.

HCA Holdings, Inc., through its subsidiaries, provides health care services in the United States. HCA Holdings has a market cap of $20.4 billion and is part of the health services industry. The company has a P/E ratio of 14.6, below the S&P 500 P/E ratio of 17.7. Shares are up 55.4% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate HCA Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates HCA Holdings as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and poor profit margins. Get the full HCA Holdings Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Amgen ( AMGN) is down $1.05 (-0.9%) to $112.98 on light volume. Thus far, 817,609 shares of Amgen exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $112.52-$114.72 after having opened the day at $114.67 as compared to the previous trading day's close of $114.03.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $84.9 billion and is part of the drugs industry. The company has a P/E ratio of 17.8, above the S&P 500 P/E ratio of 17.7. Shares are up 30.6% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade